Amedica Corporation, a biomaterial company headquartered in Salt Lake City, Utah, has entered into a distribution agreement with K2M to provide access in Europe to Amedica’s Silicon Nitride interbody spinal fusion devices. K2M is the world’s largest privately held spinal device company.
Earlier this year, Amedica and K2M conducted a pilot program in select markets in Europe where surgeons integrated Amedica’s Silicon Nitride interbody devices into their offerings for patients suffering from a variety of disorders requiring spinal fusion. According to company officials, the pilot program demonstrated a need in these strategic markets for spinal fusion devices devised from a different biomaterial.
“K2M is committed to providing the best and most innovative technologies to meet the needs of patients around the world suffering from spinal disorders and we believe our relationship with Amedica will help us further this goal, ” said Eric Major, K2M’s president and CEO.
“K2M has an outstanding sales and marketing team that has created a global reputation for providing leading edge technology to their customers. Our Silicon Nitride interbody product line will be integrated into K2M’s current portfolio of interbody spinal fusion devices, ” said Eric K. Olson, Amedica president and CEO. “We believe that there is a need in Europe for interbody fusion devices that exceed the capabilities of existing PEEK and Titanium-based devices, ” he said. “With this distribution channel in place, we believe Silicon Nitride interbody spinal fusion devices will increasingly be the solution that surgeons rely on to deliver optimal patient outcomes in spinal fusion procedures.” Amedica is a privately owned company that was founded in 1996.
